Scientific corner

Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Miki Koroku 1Teppei Omori 1Harutaka Kambayashi 1Shun Murasugi 1Tomoko Kuriyama 1Yuichi Ikarashi 1Maria Yonezawa 1Ken Arimura 2Kazunori Karasawa 3Norio Hanafusa 4Masatoshi Kawana 5Katsutoshi Tokushige 

Intest Res 2022 Jan;20(1):150-155. doi: 10.5217/ir.2020.00148. Epub 2021 Mar 12

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

https://pubmed.ncbi.nlm.nih.gov/33902268/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831771/

Scientific corner

Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19

Miki Koroku 1Teppei Omori 1Harutaka Kambayashi 1Shun Murasugi 1Tomoko Kuriyama 1Yuichi Ikarashi 1Maria Yonezawa 1Ken Arimura 2Kazunori Karasawa 3Norio Hanafusa 4Masatoshi Kawana 5Katsutoshi Tokushige 1 Intest Res. 2021 Mar 12. doi: 10.5217/ir.2020.00148.

In conclusion, our patient’s case indicates that GMA for a patient with both active UC and COVID-19 is a safe treatment option for active UC that could lead other patients in this condition to remission.

https://pubmed.ncbi.nlm.nih.gov/33902268/

https://irjournal.org/upload/pdf/ir-2020-00148.pdf

Scientific corner

Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19

Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi.

Intestinal Research. 2021 DOI:10.5217/ir.2020.00148.

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

https://www.irjournal.org/journal/view.php?doi=10.5217/ir.2020.00148

https://www.irjournal.org/upload/pdf/ir-2020-00148.pdf

Scientific corner

Adsorptive granulocyte and monocyte apheresis: A potentially relevant therapeutic option for COVID-19

Takuro Kanekura 1Koichi Kawahara 2 , Int J Infect Dis 2020 Oct;99:1-2. 

To our knowledge, GMA has a good safety profile; serious adverse effects are rarely reported. Its modes of action together with the findings of this case report support our notion that GMA is a relevant therapeutic option for patients with COVID-19 and warrants an immediate clinical trial to evaluate its full therapeutic efficacy in a large cohort of COVID-19 patients.

https://pubmed.ncbi.nlm.nih.gov/32721534/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834290/pdf/main.pdf

Contact UsFor more information

Contact Us